ROSG 0.35$
Rosetta Genomics to Present Multiple Poster Presentations at the 101st Annual Meeting of the United States and Canadian Academy of Pathology
miRview mets2 Demonstrates 92% Concordance With Clinical and Pathological Testing in Cancer of Unknown Primary
[Blocked Image: http://mw3.wsj.net/MW5/content…es/PR-Logo-Marketwire.gif]
PHILADELPHIA, PA and REHOVOT, ISRAEL, Mar 19, 2012 (MARKETWIRE via COMTEX) -- Rosetta GenomicsROSG +20.99% , a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that data from several studies demonstrating the clinical utility of the Company's miRview(R) products to identify and classify a variety of cancers will be presented by Mats Sanden, M.D., D.D.S., FCAP, Medical & Laboratory Director of Rosetta Genomics, at the 101st Annual Meeting of the United States and Canadian Academy of Pathology taking place from March 17-23, 2012 in Vancouver, British Columbia.
"We are very pleased to share these highly positive and clinically relevant results that support the utility of our miRview(R) diagnostic tests to accurately identify and classify various cancers with this distinguished audience of clinical pathologists. In particular, we are excited to present new and compelling data from studies of our miRview(R) mets^2 test to identify the tissue of origin in Cancer of Unknown Primary ("CUP") patients. In this study, we demonstrate a 92% concordance with the diagnosis based on all the clinical and pathological information available including follow-up and outcome data. We believe this is the highest percentage of concordance of any CUP test available and demonstrates that microRNA profiling with miRview(R) mets^2 can be a useful adjunct to traditional clinical and pathologic evaluation for CUP cases. With approximately 200,000 CUP and difficult to diagnose metastatic cancer patients per year in the United States, this represents a significant near-term market opportunity," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
"This growing body of clinical and scientific data also enhances our commercial efforts by providing our sales team with the clinical support needed for the increased adoption of our miRview diagnostics in oncology," added Mr. Berlin.
A study highlighting the clinical utility of the Company's miRview(R) mets^2 to identify the tissue of origin in Cancer of Unknown Primary patients in a poster entitled "A novel microRNA-based test demonstrates 92% accuracy in classification of metastatic tumors from patients diagnosed with carcinoma of unknown primary," will be presented at:
Session: Poster Session III
Number: #267
Date/Time: Tuesday, March 20th; 9:30a.m. - 12:00 p.m.
Location: Room CC Exhibit Hall B3 + C
A study demonstrating the ability of miRview(R) lung to classify lung cancer in a poster entitled "New microRNA-based diagnostic test for lung cancer classification," will be presented at:
Session: Poster Session III
Number: #312
Date/Time: Tuesday, March 20th; 9:30 a.m. - 12:00 p.m.
Location: Room CC Exhibit Hall B3 + C
A study demonstrating the clinical utility of the Company's miRview(R) kidney to classify kidney tumor types entitled "A microRNA-based diagnostic test for kidney tumor classification" will be presented at:
Session: Platform Session
Type: Presentation
Date/Time: Tuesday, March 20th; 9:15 a.m. - 9:30 a.m.
Location: Section A
http://bit.ly/FS7uJC
mal gucken, morgen 20.03. gibts anscheinend Daten. Kleine zockerposi nach 4 wochen trading pause. 
hello @ all.